DCTH Stock Analysis: Delcath Systems | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 518m USD | 12M Return: 136.3% | US24661P8077 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.69M
Qual. Beats: 2
Rev. Trend: 93.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Delcath Systems, Inc. (NASDAQ: DCTH) is a small-cap U.S. interventional oncology company that develops treatments for primary and metastatic liver cancers, operating in both the United States and Europe. Its lead product, the HEPZATO KIT, is a drug-device combination that delivers high-dose melphalan chemotherapy directly to the liver while limiting systemic exposure. The company is also conducting the FOCUS clinical trial in metastatic hepatic dominant Uveal Melanoma and markets the underlying delivery system in Europe under the CHEMOSAT name.
The company was founded in 1988 and is headquartered in Queensbury, New York, with a market capitalization of approximately $551 million. Its business model combines pharmaceutical and medical device elements, positioning it within the Health Care Equipment sub-industry.
- HEPZATO KIT launch drives early U.S. commercial revenue ramp
- European CHEMOSAT adoption expands liver cancer treatment volumes
- FOCUS trial data readouts influence regulatory and reimbursement pathways
| Net Income: 532k TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 9.47 > 1.0 |
| NWC/Revenue: 122.9% < 20% (prev 146.7%; Δ -23.82% < -1%) |
| CFO/TA 0.14 > 3% & CFO 19.6m > Net Income 532k |
| Net Debt (-93.4m) to EBITDA (1.79m): -52.08 < 3 |
| Current Ratio: 9.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.8m) vs 12m ago -1.25% < -2% |
| Gross Margin: 87.05% > 18% (prev 85.86%; Δ 1.19% > 0.5%) |
| Asset Turnover: 75.16% > 50% (prev 60.10%; Δ 15.07% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.86 (Total Current Assets 130.5m - Total Current Liabilities 13.3m) / Total Assets 137.0m |
| B: -3.85 (Retained Earnings -527.2m / Total Assets 137.0m) |
| C: 0.01 (EBIT TTM 1.29m / Avg Total Assets 126.9m) |
| D: 7.63 (Book Value of Equity 121.1m / Total Liabilities 15.9m) |
| Altman-Z'' = 1.15 = BB |
As of November 10, 2026, the stock is trading at USD 20.27 with a total of 3,444,365 shares traded. Over the past week, the price has changed by +41.85%, over one month by +31.97%, over three months by +21.60% and over the past year by +136.25%.
Current recommended Stop Loss: 19.50 (which is 3.8% or 1.3 ATR below the current price).
Delcath Systems has received a consensus analysts rating of 4.80. Therefore, it is recommended to buy DCTH.
- StrongBuy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24 | 18.4% |
P/E Trailing = 1493.0001
P/E Forward = 227.2727
P/S = 5.4293
P/B = 4.2792
P/EG = 1.5966
Revenue TTM = 95.4m USD
EBIT TTM = 1.29m USD
EBITDA TTM = 1.79m USD
Long Term Debt = 2.27m USD (estimated: total debt 2.46m - short term 196k)
Short Term Debt = 196k USD (from shortTermDebt, last quarter)
Debt = 2.46m USD (from shortLongTermDebtTotal, last quarter) (leases 2.46m already included)
Net Debt = -93.4m USD (calculated: Debt 2.46m - CCE 95.9m)
Enterprise Value = 424.6m USD (518.1m + Debt 2.46m - CCE 95.9m)
Interest Coverage Ratio = unknown (Ebit TTM 1.29m / Interest Expense TTM 0.0)
EV/FCF = 24.25x (Enterprise Value 424.6m / FCF TTM 17.5m)
FCF Yield = 4.12% (FCF TTM 17.5m / Enterprise Value 424.6m)
FCF Margin = 18.35% (FCF TTM 17.5m / Revenue TTM 95.4m)
Net Margin = 0.56% (Net Income TTM 532k / Revenue TTM 95.4m)
Gross Margin = 87.05% ((Revenue TTM 95.4m - Cost of Revenue TTM 12.4m) / Revenue TTM)
Gross Margin QoQ = 89.75% (prev 85.05%)
Tobins Q-Ratio = 3.10 (Enterprise Value 424.6m / Total Assets 137.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.46m)
Taxrate = 15.54% (491k / 3.16m)
NOPAT = 1.09m (EBIT 1.29m * (1 - 15.54%))
Current Ratio = 9.83 (Total Current Assets 130.5m / Total Current Liabilities 13.3m)
Debt / Equity = 0.02 (Debt 2.46m / totalStockholderEquity, last quarter 121.1m)
Debt / EBITDA = -52.08 (Net Debt -93.4m / EBITDA 1.79m)
Debt / FCF = -5.34 (Net Debt -93.4m / FCF TTM 17.5m)
Total Stockholder Equity = 115.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.42% (Net Income 532k / Total Assets 137.0m)
RoE = 0.46% (Net Income TTM 532k / Total Stockholder Equity 115.0m)
RoCE = 1.10% (EBIT 1.29m / Capital Employed (Equity 115.0m + L.T.Debt 2.27m))
RoIC = 0.92% (NOPAT 1.09m / Invested Capital 119.2m)
WACC = 10.58% (E(518.1m)/V(520.5m) * Re(10.63%) + D(2.46m)/V(520.5m) * Rd(0.0%) * (1-Tc(0.16)))
Discount Rate = 10.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.55 | Cagr: 23.15%
[DCF] Terminal Value 71.11% ; FCFF base≈12.1m ; Y1≈13.8m ; Y5≈20.3m
[DCF] Fair Price = 9.02 (EV 219.4m - Net Debt -93.4m = Equity 312.8m / Shares 34.7m; r=10.58% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.21 | # QB: 2
Revenue Correlation: 93.87 | Revenue CAGR: 361.6% | SUE: 0.24 | # QB: 0
EPS current Year (2026-12-31): EPS=-0.15 | Chg30d=-9.26% | Revisions=-62% | GrowthEPS=-284.4% | GrowthRev=+24.6%
EPS next Year (2027-12-31): EPS=0.04 | Chg30d=-5.56% | Revisions=-57% | GrowthEPS=+128.8% | GrowthRev=+24.3%
[Analyst] Revisions Ratio: -75% (up=0, down=9)